Home to some of the world's most important international health institutions, as well as two of its largest pharmaceutical companies in Novartis and Roche, and with a number one ranking globally in terms of ease of doing business and innovation; Switzerland can truly lay claim to be a healthcare and life sciences powerhouse. Despite some of the highest operating costs of any country in the world, an increasing number of pharma companies are choosing to base their European and EMEA headquarters in Switzerland.
Regulatory affairs plays a crucial role in the pharmaceutical industry and is involved in all stages of drug development and also after drug approval and marketing. At any time, there are more than 300,000 clinical studies happening around the world. The process for bringing new pharmaceuticals to the market is prolonged due to regulation placed on the drugs sector to protect public safety. State regulations in Switzerland can lead to high administrative costs or preclude market access. However, at the same time, regulations can also promote competition and economy-friendly structures.
Under the Swiss regulatory approach, the drugs approvals process is quick and simple. Typically, it takes around 11 months to obtain a license from the country's medicines agency, Swissmedic, one of the fastest turnaround times in the world. Swissmedic is the national authorisation and supervisory authority for drugs and medical products. The agency ensures that only high-quality, safe and effective medical products are available in Switzerland, thus making an important contribution to the protection of human and animal health.
Our Zurich based consultants are specialists in their markets, recruiting top talent for the regulatory jobs market throughout Switzerland and Europe.
